Literature DB >> 29567776

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Sigrun Thorsteinsdottir1,2, Paul W Dickman3, Ola Landgren4, Cecilie Blimark5, Malin Hultcrantz4,6, Ingemar Turesson7, Magnus Björkholm6, Sigurdur Y Kristinsson8,2,6.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29567776      PMCID： PMC6119139          DOI： 10.3324/haematol.2017.183475

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Kelly Godby; Shaji K Kumar; Luciano J Costa
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

Review 2.  Where we were, where we are, where we are going: progress in multiple myeloma.

Authors:  P Leif Bergsagel
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Can multiple myeloma become a curable disease?

Authors:  Jesús F San-Miguel; María-Victoria Mateos
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

5.  Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.

Authors:  Luciano J Costa; Parameswaran N Hari; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2016-04-22

6.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

Review 7.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Authors:  Antonio Palumbo; S Vincent Rajkumar; Jesus F San Miguel; Alessandra Larocca; Ruben Niesvizky; Gareth Morgan; Ola Landgren; Roman Hajek; Hermann Einsele; Kenneth C Anderson; Meletios A Dimopoulos; Paul G Richardson; Michele Cavo; Andrew Spencer; A Keith Stewart; Kazuyuki Shimizu; Sagar Lonial; Pieter Sonneveld; Brian G M Durie; Philippe Moreau; Robert Z Orlowski
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

Review 8.  Interpreting trends in cancer patient survival.

Authors:  P W Dickman; H-O Adami
Journal:  J Intern Med       Date:  2006-08       Impact factor: 8.989

9.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

Authors:  Milena Sant; Pamela Minicozzi; Morgane Mounier; Lesley A Anderson; Hermann Brenner; Bernd Holleczek; Rafael Marcos-Gragera; Marc Maynadié; Alain Monnereau; Gemma Osca-Gelis; Otto Visser; Roberta De Angelis
Journal:  Lancet Oncol       Date:  2014-07-13       Impact factor: 41.316

10.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Paul W Dickman; Asa Rangert Derolf; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544
View more
  25 in total

Review 1.  Reconstructing the evolutionary history of multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Eileen M Boyle; Gareth J Morgan
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

Review 2.  Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Authors:  Ingemar Turesson; Magnus Bjorkholm; Cecilie Hveding Blimark; Sigurdur Kristinsson; Ramon Velez; Ola Landgren
Journal:  Eur J Haematol       Date:  2018-04-20       Impact factor: 2.997

3.  What to do with minimal residual disease testing in myeloma.

Authors:  Elisabet E Manasanch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ingigerður S Sverrisdóttir; Sigrún H Lund; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin; Ola Landgren; Sigurður Y Kristinsson
Journal:  Br J Haematol       Date:  2019-03-24       Impact factor: 6.998

Review 5.  Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Authors:  Philippe Moreau; Shaji Kumar; Ralph Boccia; Shinsuke Iida; Hartmut Goldschmidt; Kim Cocks; Andrew Trigg; Anita Zahlten-Kumeli; Emre Yucel; Sumeet S Panjabi; Meletios Dimopoulos
Journal:  Leukemia       Date:  2019-05-15       Impact factor: 11.528

7.  Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study.

Authors:  D-Y-L Chang-Chan; R Ríos-Tamayo; M Rodríguez Barranco; D Redondo-Sánchez; Y González; R Marcos-Gragera; M J Sánchez
Journal:  Clin Transl Oncol       Date:  2021-01-12       Impact factor: 3.405

8.  Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.

Authors:  Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

9.  Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Authors:  Sæmundur Rögnvaldsson; Thorvardur Jon Love; Sigrun Thorsteinsdottir; Elín Ruth Reed; Jón Þórir Óskarsson; Íris Pétursdóttir; Guðrún Ásta Sigurðardóttir; Brynjar Viðarsson; Páll Torfi Önundarson; Bjarni A Agnarsson; Margrét Sigurðardóttir; Ingunn Þorsteinsdóttir; Ísleifur Ólafsson; Ásdís Rósa Þórðardóttir; Elías Eyþórsson; Ásbjörn Jónsson; Andri S Björnsson; Gunnar Þór Gunnarsson; Runólfur Pálsson; Ólafur Skúli Indriðason; Gauti Kjartan Gíslason; Andri Ólafsson; Guðlaug Katrín Hákonardóttir; Manje Brinkhuis; Sara Lovísa Halldórsdóttir; Tinna Laufey Ásgeirsdóttir; Hlíf Steingrímsdóttir; Ragnar Danielsen; Inga Dröfn Wessman; Petros Kampanis; Malin Hulcrantz; Brian G M Durie; Stephen Harding; Ola Landgren; Sigurður Yngvi Kristinsson
Journal:  Blood Cancer J       Date:  2021-05-17       Impact factor: 11.037

10.  Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma.

Authors:  Hira S Mian; Mark A Fiala; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.